EP2403833A4 - 8-substituted quinolines and related analogs as sirtuin modulators - Google Patents

8-substituted quinolines and related analogs as sirtuin modulators

Info

Publication number
EP2403833A4
EP2403833A4 EP10749227A EP10749227A EP2403833A4 EP 2403833 A4 EP2403833 A4 EP 2403833A4 EP 10749227 A EP10749227 A EP 10749227A EP 10749227 A EP10749227 A EP 10749227A EP 2403833 A4 EP2403833 A4 EP 2403833A4
Authority
EP
European Patent Office
Prior art keywords
related analogs
substituted quinolines
sirtuin modulators
sirtuin
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10749227A
Other languages
German (de)
French (fr)
Other versions
EP2403833A1 (en
Inventor
Chi B Vu
Rebecca L Casaubon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtris Pharmaceuticals Inc
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of EP2403833A1 publication Critical patent/EP2403833A1/en
Publication of EP2403833A4 publication Critical patent/EP2403833A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP10749227A 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators Withdrawn EP2403833A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15674909P 2009-03-02 2009-03-02
PCT/US2010/025963 WO2010101949A1 (en) 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators

Publications (2)

Publication Number Publication Date
EP2403833A1 EP2403833A1 (en) 2012-01-11
EP2403833A4 true EP2403833A4 (en) 2012-08-29

Family

ID=42709991

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10749227A Withdrawn EP2403833A4 (en) 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators

Country Status (11)

Country Link
EP (1) EP2403833A4 (en)
JP (1) JP2012519211A (en)
KR (1) KR20110128908A (en)
CN (1) CN102414180A (en)
AU (1) AU2010221417A1 (en)
BR (1) BRPI1011477A2 (en)
CA (1) CA2754058A1 (en)
EA (1) EA201171098A1 (en)
IL (1) IL214943A0 (en)
MX (1) MX2011009213A (en)
WO (1) WO2010101949A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586459T3 (en) 2008-05-01 2016-10-14 Glaxosmithkline Llc Quinolines and related analogues as sirtuin modulators
CA2729128C (en) 2008-07-03 2016-05-31 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
MX2011003373A (en) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinone, quinolone and related analogs as sirtuin modulators.
MX2012004995A (en) 2009-10-29 2012-10-03 Sirtris Pharmaceuticals Inc Bicyclic pyridines and analogs as sirtuin modulators.
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
CN103502221B (en) 2011-03-18 2016-03-30 拜耳知识产权有限责任公司 N- (3-carbamoylphenyl) -1H-pyrazole-5-carboxamide derivatives and their use for controlling animal pests
CN102250151B (en) * 2011-05-17 2013-11-06 中国科学院化学研究所 2-arimid-8-benzimidazol quinoline transition metal compound and preparation method and use thereof
MX2014002542A (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
JP6073343B2 (en) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Substituted bicyclic azaheterocycles and analogs as sirtuin regulators
JP2014530870A (en) * 2011-10-20 2014-11-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Substituted bicyclic azaheterocycles and analogs as sirtuin regulators
EP2825533B1 (en) 2012-03-13 2016-10-19 Basf Se Fungicidal pyrimidine compounds
CN104812387A (en) * 2012-11-20 2015-07-29 霍夫曼-拉罗奇有限公司 Substituted 1,6-naphthyridines
PT2970272T (en) 2013-03-14 2019-06-05 Merck Patent Gmbh Glycosidase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
TWI529171B (en) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-naphthyridine derivatives
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
CA2923101A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
JP6112724B2 (en) * 2013-10-31 2017-04-12 日本化薬株式会社 1,5-naphthyridine derivative and insecticide comprising the same as an active ingredient
MX2016006052A (en) * 2013-11-12 2016-07-18 Hoffmann La Roche Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders.
AR099120A1 (en) 2014-01-20 2016-06-29 Bayer Cropscience Ag DERIVATIVES OF QUINOLINE AS INSECTICIDES AND ACARICIDES
US9688699B2 (en) 2014-02-19 2017-06-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
EP2991990B1 (en) 2014-05-23 2017-02-01 Active Biotech AB Novel compounds useful as s100-inhibitors
JP2017522324A (en) * 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Novel naphthyridine and isoquinoline and their use as CDK8 / 19 inhibitors
JP6759514B2 (en) 2014-08-01 2020-09-23 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ Compounds active against bromodomain
EP3868752A1 (en) 2014-08-28 2021-08-25 Asceneuron SA Glycosidase inhibitors
EP3227287B1 (en) 2014-12-02 2019-08-07 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
CN104592109A (en) * 2015-01-19 2015-05-06 湖南华腾制药有限公司 Method for preparing 8-bromoquinoline derivative
EP3256217A1 (en) * 2015-02-11 2017-12-20 Basilea Pharmaceutica International AG Substituted mono- and polyazanaphthalene derivatives and their use
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
SG11201807012QA (en) 2016-02-25 2018-09-27 Asceneuron S A Acid addition salts of piperazine derivatives
CN108884078A (en) 2016-02-25 2018-11-23 阿森纽荣股份公司 Glycosidase inhibitor
AU2017222958B2 (en) 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. Linear glycosidase inhibitors
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
IL280841B2 (en) 2018-08-22 2024-12-01 Asceneuron S A Succinate and fumarate acid addition salts of piperazine derivatives used as glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
KR20210143783A (en) * 2019-02-28 2021-11-29 케자르 라이프 사이언스 Thiazole derivatives as inhibitors of protein secretion
CN110964011B (en) * 2019-12-16 2022-06-21 诚达药业股份有限公司 Synthetic method of 8-chloro-1, 7-naphthyridine-3-formaldehyde
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
CR20230057A (en) 2020-07-02 2023-08-15 Incyte Corp Tricyclic urea compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (en) 2021-02-25 2023-07-05 Incyte Corp SPIROCYCLIC LACTAMS AS JAK2 INHIBITORS V617F
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2024059216A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
WO2024059212A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2024264503A1 (en) * 2023-04-23 2025-12-04 Suzhou Genhouse Bio Co., Ltd. Amide compound, pharmaceutical composition comprising same, and use thereof
CN117362286B (en) * 2023-12-08 2024-03-12 清华大学 Compounds with SIRT6 agonistic activity and their uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029318A1 (en) * 1997-12-11 1999-06-17 Biochem Pharma Inc. Antiviral compounds
WO2003037872A1 (en) * 2001-11-01 2003-05-08 Astrazeneca Ab Therapeutic quinoline compounds with 5-ht-antagonistic properties
WO2004080463A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
US20060183909A1 (en) * 2001-07-20 2006-08-17 Martine Schmitt Compositions derived from quinoline and quinoxaline, preparation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282506B2 (en) * 2004-08-03 2007-10-16 Serenex, Inc. 2,8-disubstituted naphthyridine derivatives
EP1856099A2 (en) * 2005-03-03 2007-11-21 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
MX2010009518A (en) * 2008-02-28 2010-09-14 Novartis Ag Quinolines as inhibitors of farnesyl pyrophosphate synthase.
ES2586459T3 (en) * 2008-05-01 2016-10-14 Glaxosmithkline Llc Quinolines and related analogues as sirtuin modulators
MX2011003373A (en) * 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinone, quinolone and related analogs as sirtuin modulators.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029318A1 (en) * 1997-12-11 1999-06-17 Biochem Pharma Inc. Antiviral compounds
US20060183909A1 (en) * 2001-07-20 2006-08-17 Martine Schmitt Compositions derived from quinoline and quinoxaline, preparation and use thereof
WO2003037872A1 (en) * 2001-11-01 2003-05-08 Astrazeneca Ab Therapeutic quinoline compounds with 5-ht-antagonistic properties
WO2004080463A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010101949A1 *

Also Published As

Publication number Publication date
MX2011009213A (en) 2011-12-14
BRPI1011477A2 (en) 2016-03-22
IL214943A0 (en) 2011-11-30
CN102414180A (en) 2012-04-11
WO2010101949A1 (en) 2010-09-10
AU2010221417A1 (en) 2011-09-22
CA2754058A1 (en) 2010-09-10
EA201171098A1 (en) 2012-04-30
KR20110128908A (en) 2011-11-30
JP2012519211A (en) 2012-08-23
EP2403833A1 (en) 2012-01-11

Similar Documents

Publication Publication Date Title
IL214943A0 (en) 8-substituted quinolines and related analogs as sirtuin modulators
IL208997A0 (en) Quinolines and related analogs as sirtuin modulators
IL219372A0 (en) Bicyclic pyridines and analogs as sirtuin modulators
IL209567A0 (en) Imidazopyridine and related analogs as sirtuin modulators
AP2948A (en) Thienopyrmidinedione derivatives as TRPA1 modulators
IL218770A0 (en) Novel modulators
LT2496567T (en) Novel benzopyran kinase modulators
ZA201109535B (en) Game system
IL210206A0 (en) Benzimidazoles and related analogs as sirtuin modulators
EP2350051A4 (en) Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
IL215179A0 (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
GB0909909D0 (en) Microcapsules containing microrgnisms
SG10201402723QA (en) Flavonoid hydrogel
IL216176A0 (en) Lxr modulators
PL2496340T3 (en) Silica dispersion
GB0920846D0 (en) Defenin inducing agent
GB0919414D0 (en) Flame effect
AU328865S (en) Nasal plug
GB0920540D0 (en) Helmet
GB0918104D0 (en) Helmet
HU0900183V0 (en) Jewellery for measuring vital parameters
TWM369905U (en) Improved detachable hanging band
GB0902541D0 (en) Methods to identify modulators
AU331514S (en) Jewellery
GB0911268D0 (en) Game system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA ME RS

A4 Supplementary search report drawn up and despatched

Effective date: 20120731

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/02 20060101ALI20120725BHEP

Ipc: A61K 31/4709 20060101ALI20120725BHEP

Ipc: A61P 9/00 20060101ALI20120725BHEP

Ipc: A61K 31/506 20060101ALI20120725BHEP

Ipc: A61K 31/497 20060101ALI20120725BHEP

Ipc: A61K 31/47 20060101ALI20120725BHEP

Ipc: A61K 31/538 20060101ALI20120725BHEP

Ipc: C07D 487/04 20060101ALI20120725BHEP

Ipc: C07D 417/12 20060101ALI20120725BHEP

Ipc: A61K 31/5377 20060101ALI20120725BHEP

Ipc: A61P 3/00 20060101ALI20120725BHEP

Ipc: A61K 31/501 20060101ALI20120725BHEP

Ipc: C07D 401/14 20060101ALI20120725BHEP

Ipc: C07D 215/48 20060101AFI20120725BHEP

Ipc: A61P 5/50 20060101ALI20120725BHEP

Ipc: A61K 31/4375 20060101ALI20120725BHEP

Ipc: C07D 413/14 20060101ALI20120725BHEP

Ipc: A61K 31/519 20060101ALI20120725BHEP

Ipc: C07D 401/12 20060101ALI20120725BHEP

Ipc: C07D 417/14 20060101ALI20120725BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130228